Genetic Association Analysis of Neuronal Nitric Oxide Synthase Gene Polymorphism with Tardive Dyskinesia

NeuroMolecular Medicine

Volumn 5, Issue 2, 2004, Pages 163-169

  Shinkai, Takahiro ^a,b   Ohmori, Osamu ^a,c   Matsumoto, Chima ^a   Hori, Hiroko ^a   Kennedy, James L ^b   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF TORONTO   (Canada)

^c Wakato Hospital   (Japan)

Author keywords

Genetic association; Nitric oxide; Nitric oxide synthase; Oxidative stress; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; RESTRICTION ENDONUCLEASE;

ADULT; AGED; ARTICLE; DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

AGED; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN CHEMISTRY; DNA MUTATIONAL ANALYSIS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 2342523372     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/NMM:5:2:163     Document Type: Article

References (55)

1. Andreassen, O.A. and Jorgensen, H.A. (2000) Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61, 525-541.
2. Basile, V. S., Özdemir, V., Masellis M., et al. (2000) A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry 5, 410-417.
3. Behl, C., Rupprecht, R., Skutella, T., and Holsboer, F. (1995) Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. Neuroreport 7, 360-364.
4. Bester, A. M. and Harvey, B. H. (2000) Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacuous chewing movements. Metab. Brain Dis. 15, 275-285.
5. Bischot, L., Van den Brink, G., and Porsius, A. J. (1993) Vitamin E in extrapyramidal disorders. Pharm. World Sci. 15, 146-150.
6. Bredt, D. S., Hwang, P. M., Glatt, C. E., et al. (1991) Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351, 714-718.
7. Butterfield, D. A., Castegna, A., Drake, J., Scapagnini G., and Calabrese V. (2002) Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr. Neurosci. 5, 229-239.
8. Casey, D. E., Gerlach, J., Magelund, G., and Christensen, T. R. (1980) Gamma-acetylenic GABA in tardive dyskinesia. Arch. Gen. Psychiatry 37, 1376-1379.
9. Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., and Snyder, S. H. (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA. 88, 6368-6371.
10. Furchgott R. F. (1990) The 1989 Ulf von Euler lecture. Studies on endothelium-dependent vasodilation and the endothelium-derived relaxing factor. Acta. Physiol. Scand. 139, 257-270.
11. Garthwaite, J., Garthwaite, G., Palmer, R.M., and Moncada, S. (1989) NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur. J. Pharmacol. 172, 413-416.
12. Glazer, W. M. (2000a) Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J. Clin. Psychiatry 61, suppl 4, 21-26.
13. Glazer, W. M. (2000b) Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J. Clin. Psychiatry, 61, suppl 3, 16-21.
14. Gracy, K. N. and Pickel, V. M. (1996) Ultrastructural immunocytochemical localization of the N-methyl-D-aspartate receptor and tyrosine hydroxylase in the shell of the rat nucleus accumbens. Brain Res. 739, 169-181.
15. Gracy, K. N. and Pickel, V. M. (1997) Ultrastructural localization and comparative distribution of nitric oxide synthase and N-methyl-D-aspartate receptors in the shell of the rat nucleus accumbens. Brain Res. 747, 259-272.
16. Grasemann, H., Yandava, C. N., and Drazen, J. M. (1999) Neuronal NO synthase (NOS1) is a major candidate gene for asthma. Clin. Exp. Allergy 29, suppl 4, 39-41.
17. Guy, W. (1976) Abnormal involuntary movement scale (AIMS), in US Department Health, Education, and Welfare: ECDEU Assessment Manual for Psychopharmacology, revised, US DWEW publication, Washington, DC, pp. 534-537.
18. Hori, H., Ohmori, O., Shinkai, T., et al. (2000) Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 23, 170-177.
19. Iadecola, C., Xu, X., Zhang, F., Hu, J., and el-Fakahany, E.E. (1994) Prolonged inhibition of brain nitric oxide synthase by short-term systemic administration of nitro-L-arginine methyl ester. Neurochem. Res. 19, 501-505.
20. Ignarro L. J. (1990) Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 30, 535-560.
21. Jackson-Lewis, V., Przedborski, S., Kostic, V., et al. (1991) Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-alpha-tocopherol in rat brain. Brain Res. Bull.26, 251-258.
22. Jeste, D. V. and Kelsoe, J. R. (1997) Schizophrenia, tardive dyskinesia, and a D3 receptor gene variant: a new twist on dyskinesias? Mol. Psychiatry 2, 86-88.
23. Kapitany, T., Meszaros, K., Lenzinger, E., et al. (1998) Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res. 32, 101-106.
24. Kishimoto, J., Spurr, N., Liao, M., et al. (1992) Localization of brain nitric oxide synthase (NOS) to human chromosome 12. Genomics 14, 802-804.
25. Krukoff, T. L. (1999) Central actions of nitric oxide in regulation of autonomic functions. Brain Res. Brain Res. Rev. 30, 52-65.
26. Latimer, P. R. (1995) Tardive dyskinesia: a review. Can. J. Psychiatry 40, suppl 2, S49-S54.
27. Lohr, J. B., Kuczenski, R., Bracha, H. S., Moir, M., and Jeste D. V. (1990) Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry 28, 535-539.
28. Lowenstein, C. J., Glatt, C. S., Bredt, D. S., and Snyder, S. H. (1992) Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc. Natl. Acad. Sci. USA 89, 6711-6715.
29. Lyons, C. R., Orloff, G. J., and Cunningham, J. M. (1992) Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J. Biol. Chem. 267, 6370-6374.
30. Meltzer, H. Y. (1994) An overview of the mechanism of action of clozapine. J. Clin. Psychiatry 55, suppl B, 47-52.
31. Miller, C. H., Simioni, I., Oberbauer, H., et al. (1995) Tardive dyskinesia prevalence rates during a ten-year follow-up. J. Nerv. Ment. Dis. 183, 404-407.
32. Moncada, S., Palmer R. M., and Higgs E. A. (1989) Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem. Pharmacol. 38, 1709-1715.
33. Morgenstern, H. and Glazer, W. M. (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry 50, 723-733.
34. Naidu, P. S and Kulkarni, S. K. (2001) Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav. Pharmacol. 12, 209-216.
35. Ohmori, O., Suzuki, T., Kojima, H., et al. (1998) Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr. Res. 32, 107-113.
36. Reif, D. W. (1993) Delayed production of nitric oxide contributes to NMDA-mediated neuronal damage. Neuroreport 4, 566-568.
37. Sandyk, R. (1993) Biological determinants and risk factors for tardive dyskinesia in schizophrenia. Int. J. Neurosci. 69, 35-51.
38. Schooler, N. R. and Kane, J.M. (1982) Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39, 486-487.
39. Schultz, S. K., Arndt, S., Ho, B. C., Oliver, S. E., and Andreasen, N. C. (1999) Impaired glucose tolerance and abnormal movements in patients with schizophrenia. Am. J. Psychiatry 156, 640-642.
40. See, R. E. (1991) Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci. Lett. 129, 265-268.
41. gly alleles to susceptibility. Psychopharmacology 152, 408-413.
42. Segman, R. H., Heresco-Levy, U., Finkel, B., et al. (2001) Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry 6, 225-229.
43. Shale, H. and Tanner, C. (1996) Pharmacological options for the management of dyskinesias. Drugs 52, 849-860.
44. Shimomura, K., Satoh, H., Hirai, O., et al. (1982) The central anti-serotonin activity of zotepine, a new neuroleptic, in rat. Jpn. J. Pharmacol. 32, 405-412.
45. Shinkai, T., Ohmori, O., Hori, H., and Nakamura, J. (2002) Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol. Psychiatry 7, 560-563.
46. Snyder, S. H. (1992) Nitric oxide: first in a new class of neurotransmitters. Science 257, 494-496.
47. Steen, V. M., Løvlie, R., MacEwan, T., and McCreadie, R. G. (1997) Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry 2, 139-145.
48. Tarsy, D. and Baldessarini, R. J. (1977) The pathophysiologic basis of tardive dyskinesia. Biol. Psychiatry 12, 431-450.
49. Toru, M. (1983) Seishinbunnretsubyo no yakuri [pharmacology in schizophrenia]. Chu-gai Igakusha Co., Tokyo
50. Tsai, G., Goff, D. C., Chang, R.W., et al. (1998) Markers of glutamatergic neurotransmission and oxidative stress associated tardive dyskinesia. Am. J. Psychiatry 155, 1207-1213.
51. Vincent, S. R. and Hope, B. T. (1992) Neurons that say NO. Trends Neurosci. 15, 108-113.
52. Xie, Q. W., Cho, H. J., Calaycay, J., et al. (1992) Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256, 225-228.
53. Yun, H. Y., Dawson, V. L., and Dawson, T. M. (1996) Neurobiology of nitric oxide. Crit. Rev. Neurobiol. 10, 291-316.
54. Yun, H. Y., Dawson, V. L., and Dawson, T. M. (1997) Nitric oxide in health and disease of the nervous system. Mol. Psychiatry 2, 300-310.
55. Zhang, Z., Zhang, X., Hou, G., Sha, W., and Reynolds, G. P. (2002) The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J. Psychiatr. Res. 36, 317-324.